Plus Therapeutics Inc (PSTV) - Total Assets
Based on the latest financial reports, Plus Therapeutics Inc (PSTV) holds total assets worth $16.32 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check PSTV cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Plus Therapeutics Inc - Total Assets Trend (1998–2025)
This chart illustrates how Plus Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Check Plus Therapeutics Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Plus Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Plus Therapeutics Inc's total assets of $16.32 Million consist of 92.9% current assets and 7.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 53.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $333.00K | 2.0% |
| Goodwill | $372.00K | 2.3% |
Asset Composition Trend (1998–2025)
This chart illustrates how Plus Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Plus Therapeutics Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Plus Therapeutics Inc's current assets represent 92.9% of total assets in 2025, an increase from 3.4% in 1998.
- Cash Position: Cash and equivalents constituted 53.7% of total assets in 2025, up from 3.4% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 1998.
- Asset Diversification: The largest asset category is goodwill at 2.3% of total assets.
Plus Therapeutics Inc Competitors by Total Assets
Key competitors of Plus Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Plus Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.23 | 0.34 | 1.86 |
| Quick Ratio | 1.23 | 0.34 | 1.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.86 Million | $-10.29 Million | $7.13 Million |
Plus Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Plus Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.51 |
| Latest Market Cap to Assets Ratio | 1.81 |
| Asset Growth Rate (YoY) | 146.1% |
| Total Assets | $16.32 Million |
| Market Capitalization | $29.58 Million USD |
Valuation Analysis
Above Book Valuation: The market values Plus Therapeutics Inc's assets above their book value (1.81x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Plus Therapeutics Inc's assets grew by 146.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Plus Therapeutics Inc (1998–2025)
The table below shows the annual total assets of Plus Therapeutics Inc from 1998 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $16.32 Million | +146.12% |
| 2024-12-31 | $6.63 Million | -41.75% |
| 2023-12-31 | $11.39 Million | -52.29% |
| 2022-12-31 | $23.87 Million | +8.58% |
| 2021-12-31 | $21.98 Million | +81.59% |
| 2020-12-31 | $12.11 Million | -47.89% |
| 2019-12-31 | $23.23 Million | -3.18% |
| 2018-12-31 | $23.99 Million | -24.12% |
| 2017-12-31 | $31.61 Million | -8.65% |
| 2016-12-31 | $34.61 Million | -8.19% |
| 2015-12-31 | $37.70 Million | -2.64% |
| 2014-12-31 | $38.72 Million | -7.94% |
| 2013-12-31 | $42.06 Million | -2.75% |
| 2012-12-31 | $43.25 Million | -16.07% |
| 2011-12-31 | $51.53 Million | -22.33% |
| 2010-12-31 | $66.35 Million | +168.08% |
| 2009-12-31 | $24.75 Million | -3.36% |
| 2008-12-31 | $25.61 Million | +19.07% |
| 2007-12-31 | $21.51 Million | -13.52% |
| 2006-12-31 | $24.87 Million | -11.71% |
| 2005-12-31 | $28.17 Million | +10.59% |
| 2004-12-31 | $25.47 Million | -9.32% |
| 2003-12-31 | $28.09 Million | -28.56% |
| 2002-12-31 | $39.32 Million | -8.86% |
| 2001-12-31 | $43.14 Million | -17.46% |
| 2000-12-31 | $52.27 Million | +837.56% |
| 1999-12-31 | $5.58 Million | +446.57% |
| 1998-12-31 | $1.02 Million | -- |
About Plus Therapeutics Inc
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric br… Read more